Inventaire - your friends and communities are your best library

Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis

author

Klemens Budde

John J Bissler

Bernard A. Zonnenberg

1951 -

published in: British Journal of Clinical Pharmacology

date of publication: 2015-11-18

language: English

main subject: tuberous sclerosis, tuberous sclerosis 1, pharmacokinetics, pharmacodynamics

Cites articles 32

Date

Title

Authors

2014-10-03

Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance

Vidya Navaratnam, Simon R. Johnson
2014-06-11

Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy

Bradley P Dixon, John J Bissler
2013-08-01

Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial

Lianne G Singer, Charlie Strange, Gregory P. Downey, Francis Mccormack, Joel Moss
2013-08-01

Lymphangioleiomyomatosis screening in women with tuberous sclerosis

John J Bissler, Francis Mccormack
2013-03-01

Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study

Jan Peveling-Oberhag, Stefan Zeuzem
2013-02-20

Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis
2013-03-01

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

John J Bissler, Elena Dmitrievna Belousova, Klemens Budde
2012-09-26

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model

Elisabeth de Vries
2012-11-03

The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM).
2011-11-29

Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition

Klemens Budde
2011

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease
2011-03-16

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

Joel Moss, Lianne G Singer, Evans R Fernández Pérez, Charlie Strange
2011-01-13

Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
2010-10-01

Tuberous sclerosis complex: neurological, renal and pulmonary manifestations
2010-11-11

Tuberous sclerosis complex renal disease.
2009-09-25

Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors

Toshihiko Doi, Atsushi Ohtsu
2008-06-01

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth
2008-03-10

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

Vassiliki Papadimitrakopoulou, Ian Judson
2008-02-01

Lymphangioleiomyomatosis: a clinical update

Francis Mccormack
2008-08-01

Tuberous sclerosis

Sergiusz Jóźwiak
2006-09-01

The tuberous sclerosis complex

Katherine L Nathanson
2006-09

Vascular Endothelial Growth Factor-D Is Increased in Serum of Patients with Lymphangioleiomyomatosis
2004-09-01

Renal angiomyolipomata

John J Bissler
2004-01-01

Clinical pharmacokinetics of everolimus
2003-09-01

Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin
2002-11-01

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
2002-10-01

Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture
2001-08-01

Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis
2001-02-01

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.
2000-06-01

High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex
2000-05-01

Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis

Aristotelis Astrinidis
1998-02-01

Angiomyolipoma of kidney

Article - wd:Q36806587

Welcome to Inventaire

the library of your friends and communities

learn more